Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Halozyme Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $102.37M, up 43.7% year over year. For fiscal 2025 it was $81.49M, up 3.1% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $150.84M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.49M | +3.1% |
| FY2024 | Dec 31, 2024 | $79.05M | +3.5% |
| FY2023 | Dec 31, 2023 | $76.36M | +14.6% |
| FY2022 | Dec 31, 2022 | $66.61M | +86.7% |
| FY2021 | Dec 31, 2021 | $35.67M | +4.2% |
| FY2020 | Dec 31, 2020 | $34.24M | -75.7% |
| FY2019 | Dec 31, 2019 | $140.80M | -6.3% |
| FY2018 | Dec 31, 2018 | $150.25M | -0.3% |
| FY2017 | Dec 31, 2017 | $150.64M | -0.1% |
| FY2016 | Dec 31, 2016 | $150.84M | +61.8% |
| FY2015 | Dec 31, 2015 | $93.24M | +17.0% |
| FY2014 | Dec 31, 2014 | $79.70M | -17.5% |
| FY2013 | Dec 31, 2013 | $96.64M | +38.0% |
| FY2012 | Dec 31, 2012 | $70.04M | +21.7% |
| FY2011 | Dec 31, 2011 | $57.56M | +11.2% |
| FY2010 | Dec 31, 2010 | $51.77M | -8.6% |
| FY2009 | Dec 31, 2009 | $56.61M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.66M | +57.7% |
| Q1 FY2026 | Mar 31, 2026 | $25.56M | +72.7% |
| Q4 FY2025 | Dec 31, 2025 | $31.90M | +56.0% |
| Q3 FY2025 | Sep 30, 2025 | $17.25M | -6.5% |
| Q2 FY2025 | Jun 30, 2025 | $17.54M | -16.6% |
| Q1 FY2025 | Mar 31, 2025 | $14.80M | -22.6% |
| Q4 FY2024 | Dec 31, 2024 | $20.44M | -4.2% |
| Q3 FY2024 | Sep 30, 2024 | $18.46M | +6.6% |
| Q2 FY2024 | Jun 30, 2024 | $21.04M | +6.6% |
| Q1 FY2024 | Mar 31, 2024 | $19.11M | +6.3% |
| Q4 FY2023 | Dec 31, 2023 | $21.34M | -5.5% |
| Q3 FY2023 | Sep 30, 2023 | $17.32M | +3.7% |
| Q2 FY2023 | Jun 30, 2023 | $19.73M | +27.4% |
| Q1 FY2023 | Mar 31, 2023 | $17.98M | +51.7% |
| Q4 FY2022 | Dec 31, 2022 | $22.57M | +123.2% |
| Q3 FY2022 | Sep 30, 2022 | $16.71M | +96.9% |
| Q2 FY2022 | Jun 30, 2022 | $15.48M | +91.9% |
| Q1 FY2022 | Mar 31, 2022 | $11.85M | +31.6% |
| Q4 FY2021 | Dec 31, 2021 | $10.11M | +37.0% |
| Q3 FY2021 | Sep 30, 2021 | $8.49M | +9.5% |
| Q2 FY2021 | Jun 30, 2021 | $8.07M | -9.9% |
| Q1 FY2021 | Mar 31, 2021 | $9.01M | -11.3% |
| Q4 FY2020 | Dec 31, 2020 | $7.38M | -83.6% |
| Q3 FY2020 | Sep 30, 2020 | $7.75M | -74.6% |
| Q2 FY2020 | Jun 30, 2020 | $8.95M | -73.6% |
| Q1 FY2020 | Mar 31, 2020 | $10.16M | -67.6% |
| Q4 FY2019 | Dec 31, 2019 | $45.11M | +23.1% |
| Q3 FY2019 | Sep 30, 2019 | $30.46M | -14.3% |
| Q2 FY2019 | Jun 30, 2019 | $33.91M | -15.4% |
| Q1 FY2019 | Mar 31, 2019 | $31.33M | -17.5% |
| Q4 FY2018 | Dec 31, 2018 | $36.65M | -11.4% |
| Q3 FY2018 | Sep 30, 2018 | $35.54M | +4.6% |
| Q2 FY2018 | Jun 30, 2018 | $40.09M | +4.6% |
| Q1 FY2018 | Mar 31, 2018 | $37.98M | +2.8% |
| Q4 FY2017 | Dec 31, 2017 | $41.38M | +0.1% |
| Q3 FY2017 | Sep 30, 2017 | $33.99M | +0.4% |
| Q2 FY2017 | Jun 30, 2017 | $38.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.94M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.35M | – |
| Q3 FY2016 | Sep 30, 2016 | $33.86M | – |
See a number that looks wrong?